Trump Administration Expands Medicare Drug Price Negotiations
6 weeks ago
The Trump administration announced that 15 additional prescription drugs will now be subject to Medicare price negotiations, including treatments for type 2 diabetes, HIV, arthritis, and cancer.
Officials say the expansion targets some of the most expensive medications in the Medicare program and could save taxpayers billions of dollars when the lower prices take effect in 2028.
The White House emphasized that the move aims to reduce costs for seniors while maintaining fairness across the healthcare system. Administration officials note that this is part of a broader effort to increase affordability and transparency in drug pricing for Medicare beneficiaries.
Officials say the expansion targets some of the most expensive medications in the Medicare program and could save taxpayers billions of dollars when the lower prices take effect in 2028.
The White House emphasized that the move aims to reduce costs for seniors while maintaining fairness across the healthcare system. Administration officials note that this is part of a broader effort to increase affordability and transparency in drug pricing for Medicare beneficiaries.
